BridgeBio Pharma, Inc. (BBIO) ownership: KKR Genetic Disorder L.P. 22% · institutions 96% · index and ETF funds 7% (13F 2026-03-31). Insider activity, 90 days: Routine (27 sales, 0 open-market buys). 6 recent congressional STOCK Act disclosures. SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| Vanguard | 17279436.00 | $1.28B | 8.8% | 2026-03-31 |
| BlackRock | 14207757.00 | $1.06B | 7.3% | 2026-03-31 |
| Kohlberg Kravis Roberts & Co. L.P. | 13260971.00 | $984.76M | 6.8% | 2026-03-31 |
| Janus Henderson | 13179013.00 | $978.61M | 6.7% | 2026-03-31 |
| Viking Global Investors LP | 11842434.00 | $879.42M | 6.1% | 2026-03-31 |
| Farallon Capital Management LLC | 9365463.00 | $695.48M | 4.8% | 2026-03-31 |
| Aisling Capital Management LP | 5089611.00 | $377.95M | 2.6% | 2026-03-31 |
| Geode Capital Management | 4918030.00 | $371.93M | 2.5% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-08-18 | |
| Sell | null | 2026-08-18 | |
| Sell | null | 2026-08-18 | |
| Sell | null | 2026-08-18 | |
| Sell | null | 2026-08-18 | |
| Sell | null | 2026-08-18 | |
| Sell | null | 2026-08-18 | |
| Sell | null | 2026-08-16 |
Back to BBIO overview · BBIO earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.